4 results
Determine the influence of methylphenidate treatment on sleep-wake rhythm and endogenous melatonin rhythm.
To better understand the utilities of the new BETACONNECT device and characterize its contribution to adherence, we plan to prospectively follow-up MS patients using the device for 24 weeks.
Primary Objective: To determine if the (change in) gut and oral microbiome at baseline or in the first 3 months after start of Cladribine is a predictor for treatment response in subjects with active relapsing remitting MS.The secondary objectives…
synopsis:Primary:• To assess the health related quality of life (HRQoL) through the MSQoL-54 scale in highly-active relapsing multiple sclerosis (RMS) subjects treated with Mavenclad® for 2 years (24 months)Secondary:• To assess treatment…